ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

… And Alnylam To MIT

by Ann M. Thayer
August 1, 2011 | APPEARED IN VOLUME 89, ISSUE 31

Alnylam Pharmaceuticals and MIT have developed new nanoparticles for the systemic delivery of RNAi therapeutics. They created core-shell nanoparticles using high-throughput polymer synthesis and then screened for those having the best properties for intracellular delivery. “Continued progress in delivery of RNAi therapeutics requires broad-based efforts around novel lipids, conjugates, and polymers,” says Kevin Fitzgerald, Alnylam’s senior director of research. The partners published their findings in the Proceedings of the National Academy of Sciences USA (DOI: 10.1073/pnas.1106379108).

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment